{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:14:17Z","timestamp":1784121257024,"version":"3.55.0"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005624","name":"Medizinischen Hochschule Hannover","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.eplepsyres.2025.107689","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:18:22Z","timestamp":1761265102000},"page":"107689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Trends, prescribing patterns and projections of antiseizure drug use in Europe"],"prefix":"10.1016","volume":"218","author":[{"given":"Lilly Josephine","family":"Bindel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9512-4870","authenticated-orcid":false,"given":"Roland","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2025.107689_bib1","unstructured":"ANDMEBAAS. (2025). Statistics on Medicines. ATC-N: Nervous system. Health Statistics and Health Research Database. Last updated: 2025. Last accessed: April 25 2025. \u3008https:\/\/statistika.tai.ee\/pxweb\/en\/Andmebaas\/Andmebaas__06Ravimistatistika__01Ravimistatistika\/ATC-N.px\/\u3009."},{"issue":"12","key":"10.1016\/j.eplepsyres.2025.107689_bib2","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1111\/epi.13210","article-title":"Availability of antiepileptic drugs across Europe","volume":"56","author":"Baftiu","year":"2015","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.eplepsyres.2025.107689_bib3","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00228-016-2092-3","article-title":"Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders-a pharmacoepidemiological study and clinical implications","volume":"72","author":"Baftiu","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.eplepsyres.2025.107689_bib4","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1528-1157.2000.tb01512.x","article-title":"The stigma of epilepsy: a european perspective","volume":"41","author":"Baker","year":"2000","journal-title":"Epilepsia"},{"issue":"11-12","key":"10.1016\/j.eplepsyres.2025.107689_bib5","first-page":"429","article-title":"Leitlinien zur pharmakologischen behandlung von epilepsie","volume":"143","author":"Ba\u0161i\u0107","year":"2021","journal-title":"Lije\u010dni\u010dki Vjesn."},{"issue":"2","key":"10.1016\/j.eplepsyres.2025.107689_bib6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1017\/S2045796016000706","article-title":"Policies, guideline implementation and practice change \u2013 how can the process be understood?","volume":"26","author":"Becker","year":"2016","journal-title":"Epidemiol. Psychiatr. Sci."},{"issue":"1","key":"10.1016\/j.eplepsyres.2025.107689_bib7","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/epi.16763","article-title":"Optimal choice of antiseizure medication: agreement among experts and validation of a web-based decision support application","volume":"62","author":"Beniczky","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.seizure.2020.10.018","article-title":"Current role of carbamazepine and oxcarbazepine in the management of epilepsy","volume":"83","author":"Beydoun","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib9","doi-asserted-by":"crossref","DOI":"10.1007\/s00210-025-04121-y","article-title":"AWaRe classification analysis for european countries with ARIMA forecasts to assess prescribing patterns and \u2018One Health\u2019 targets","author":"Bindel","year":"2025","journal-title":"NaunynSchmiede 's. Arch. Pharm."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib10","doi-asserted-by":"crossref","DOI":"10.1007\/s00210-025-03930-5","article-title":"Long-term forecasting and evaluation of Medicine consumption for the ATC class h with a focus on thyroid hormones in OECD countries using ARIMA models","author":"Bindel","year":"2025","journal-title":"NaunynSchmiede 's. Arch. Pharm."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib11","doi-asserted-by":"crossref","DOI":"10.1007\/s00210-025-04389-0","article-title":"Evidence of lithium underuse in bipolar disorder: analysis of lithium and antipsychotic consumption, prediction of future trends, regional disparities and indicators of rational and inappropriate use in Europe","author":"Bindel","year":"2025","journal-title":"NaunynSchmiede 's. Arch. Pharm."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib12","series-title":"Time Series Analysis: Forecasting and Control","author":"Box","year":"2015"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.yebeh.2014.11.015","article-title":"Epilepsy-related stigma in european people with epilepsy: correlations with health system performance and overall quality of life","volume":"42","author":"Brigo","year":"2015","journal-title":"Epilepsy Behav. EB"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.seizure.2022.06.010","article-title":"Estimates of epilepsy prevalence, psychiatric co-morbidity and cost","volume":"107","author":"Christensen","year":"2023","journal-title":"Seizure. Eur. J. Epilepsy"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib15","unstructured":"Dansk Neurologisk Selskab. (2022). National behandlings- og visitationsvejledning for epilepsi. Version 1.0. Last updated: June 2022. Last accessed: July 20 2025. \u3008https:\/\/www.epilepsiforeningen.dk\/wp-content\/uploads\/2022\/06\/National-Behandlings-og-Visitationsvejledning-for-Epilepsi_DNS_juni2022.pdf\u3009."},{"issue":"5","key":"10.1016\/j.eplepsyres.2025.107689_bib16","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/epi.12557","article-title":"Antiepileptic drug use in seven electronic health record databases in Europe: a methodologic comparison","volume":"55","author":"de Groot","year":"2014","journal-title":"Epilepsia"},{"issue":"366","key":"10.1016\/j.eplepsyres.2025.107689_bib17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2307\/2286348","article-title":"Distribution of the estimators for autoregressive time series with a unit root","volume":"74","author":"Dickey","year":"1979","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib18","unstructured":"Directorate of Health. (2025). Lyfjanotkun \u00e1 \u00cdslandi. Eftir ATC flokkunarkerfi lyfja. Last accessed: April 25 2025. Last updated: January 2025. \u3008https:\/\/app.powerbi.com\/view?r=eyJrIjoiZmRiMGJkNmMtZWQ4NC00NmUzLTlkY2UtZTQ0NDk5ZjZmMDE2IiwidCI6Ijc2NGEzMDZkLTBhNjgtNDVhZC05ZjA3LTZmMTgwNDQ0N2NkNCIsImMiOjh9\u3009."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib19","unstructured":"Dutch Healthcare Institute. (2024). GIPdatabank.nl. Last updated: May 2024. Last accessed: May 10 2025. \u3008https:\/\/www.gipdatabank.nl\/databank?infotype=g&label=00-totaal&tabel=B_01-basis&geg=ddd&item=N\u3009."},{"issue":"11","key":"10.1016\/j.eplepsyres.2025.107689_bib20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.33588\/rn.7311.2021247","volume":"73","author":"Ehlken","year":"2021","journal-title":"Rev. De. Neurol."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib21","unstructured":"EMA). (2018). PRAC recommends new measures to avoid valproate exposure in pregnancy. Last updated: February 9 2018. Last accessed: July 19 2025. \u3008https:\/\/www.ema.europa.eu\/en\/news\/prac-recommends-new-measures-avoid-valproate-exposure-pregnancy\u3009."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib22","unstructured":"Estonian State Agency of Medicines. (2013). Baltic Statistics on Medicines 2010-2012. Tartu, Estonia. ISBN 978\u20139949\u201333\u2013397\u20134. Last accessed: April 25 2025. Last updated: 2013. \u3008https:\/\/www.zva.gov.lv\/sites\/default\/files\/2018-05\/BS_2013.pdf\u3009."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib23","series-title":"Quality of Health and Care Services in The EU","author":"Eurofound","year":"2019"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib24","unstructured":"EuroHealthNet (2025). Social inequalities in health in the EU: Are countries closing the health gap? Technical report. EuroHealthNet & Centre for Health Equity Analytics (CHAIN), Brussels. Last updated: September 25 2025. Last accessed: October 6 2025. \u3008https:\/\/eurohealthnet.eu\/wp-content\/uploads\/publications\/2025\/2509_social-inequalities-in-the-eu_technical-report.pdf\u3009."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib25","unstructured":"European Parliament (2018). Centralization policies in European and North American countries. Last updated: 2018. Last accessed: October 6 2025. \u3008https:\/\/www.europarl.europa.eu\/workingpapers\/saco\/pdf\/101_en.pdf\u3009."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib26","series-title":"Database. Population (national level)","author":"Eurostat","year":"2025"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109350","article-title":"Value contribution of cenobamate for the treatment of Focal-Onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through reflective Multi-Criteria decision analysis (MCDA)","volume":"145","author":"Falip","year":"2023","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib28","unstructured":"Federatie Medisch Specialisten. (2024). Epilepsie. Richtlijnendatabase. Last updated: September 2024. Last accessed: July 20 2025. \u3008https:\/\/richtlijnendatabase.nl\/richtlijn\/epilepsie\/startpagina_-_cluster_epilepsie.html\u3009."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib29","series-title":"Norwegian Prescription Database","author":"Folkehelseinstituttet","year":"2021"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib30","series-title":"Drug Consumption in Norway 2019-2023. Data from Norwegian Drug Wholesales Statistics","author":"Folkehelseinstituttet","year":"2024"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.nrl.2013.02.006","article-title":"Perfil de consumo de antiepil\u00e9pticos en los pacientes epil\u00e9pticos del \u00c1rea oeste de M\u00e1laga","volume":"30","author":"Garcia-Martin","year":"2015","journal-title":"Neurol. \u00eda"},{"issue":"3","key":"10.1016\/j.eplepsyres.2025.107689_bib32","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S2468-2667(24)00302-5","article-title":"Global, regional, and national burden of epilepsy, 1990-2021: a systematic analysis for the global burden of disease study 2021","volume":"10","author":"GBD Epilepsy Collaborators","year":"2025","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib33","unstructured":"GitHub. (2025). PDMARIMA: Issue Importing Pmdarima in Google Colab #9539. Last updated: March 20 2025. Last accessed: May 27 2025. \u3008https:\/\/github.com\/statsmodels\/statsmodels\/issues\/9539\u3009."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib34","first-page":"Doc09","article-title":"Real life pharmaceutical treatment patterns for adult patients with focal epilepsy in Germany: a longitudinal and cross-sectional analysis of recently approved anti-epileptic drugs","volume":"15","author":"Groth","year":"2017","journal-title":"German Med. Sci. Gms E-Journal"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib35","unstructured":"HALMED). (2014). Potro\u0161nja lijekova u Hrvatskoj 2007 - 2012. godine Last updated: 2014. Last accessed: May 11 2025. \u3008https:\/\/www.halmed.hr\/fdsak3jnFsk1Kfa\/publikacije\/Potrosnja_lijekova_u_Hrvatskoj_2007-2012.pdf\u3009."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib36","unstructured":"HALMED). (2018). Potro\u0161nja lijekova u Hrvatskoj 2013 \u2013 2017. Last updated: 2018. Last accessed: May 11 2025. \u3008https:\/\/www.halmed.hr\/fdsak3jnFsk1Kfa\/publikacije\/Potrosnja-lijekova-u-Hrvatskoj-2013-2017.pdf\u3009."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib37","unstructured":"HALMED). (2023). Potro\u0161nja lijekova u Hrvatskoj 2018 \u2013 2022. Last updated: 2023. Last accessed: May 11 2025. \u3008https:\/\/www.halmed.hr\/fdsak3jnFsk1Kfa\/publikacije\/Potrosnja-lijekova-u-Hrvatskoj-2018-2022.pdf\u3009."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib38","doi-asserted-by":"crossref","DOI":"10.1177\/20503121231218985","article-title":"Shedding light on neuropathic pain: current and emerging tools for diagnosis, screening, and quantification","volume":"12","author":"Hamdan","year":"2024","journal-title":"SAGE Open Med."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib39","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41582-021-00555-z","article-title":"Neurobehavioural comorbidities of epilepsy: towards a network-based precision taxonomy","volume":"17","author":"Hermann","year":"2021","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.eplepsyres.2025.107689_bib40","first-page":"8089","article-title":"Quality of epilepsy care in a rural and deprived scottish population","volume":"23","author":"Holden","year":"2023","journal-title":"Rural Remote Health"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib41","unstructured":"Holtkamp M., May T.W., Berkenfeld R., Bien C.G., Coban I., Knake S., Michaelis R., R\u00e9mi J., Seeck M., Surges R., Weber Y., et al. (2023). Erster epileptischer Anfall und Epilepsien im Erwachsenenalter, S2k-Leitlinie, 2023; in: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. AWMF-Registernummer: 030\/041. Last updated: September 2023. Last accessed: July 20 2025. \u3008https:\/\/dgn.org\/leitlinie\/erster-epileptischer-anfall-und-epilepsien-im-erwachsenenalter\u3009."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108549","article-title":"Twenty-year trends in the use of anti-seizure medication among pregnant women in the Netherlands","volume":"127","author":"Houben","year":"2022","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib43","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.seizure.2024.10.002","article-title":"Prehospital seizure management protocols need standardized guidelines. A descriptive study from Norway","volume":"123","author":"Hustad","year":"2024","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib44","series-title":"Forecasting: Principles and Practice","author":"Hyndman","year":"2021"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib45","unstructured":"IBM. (2021). Time Series Model. IBM SPSS Modeler. Last updated: August 17 2021. Last accessed: May 29 2025. \u3008https:\/\/www.ibm.com\/docs\/hr\/spss\u3009-."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib46","unstructured":"IHME). (2024). GBD results. Idiopathic epilepsy. University of Washington. Last updated: May 16 2024. Last accessed: May 11 2025. \u3008https:\/\/vizhub.healthdata.org\/gbd-results\/\u3009."},{"issue":"9","key":"10.1016\/j.eplepsyres.2025.107689_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2589","article-title":"The burden of epilepsy and unmet need in people with focal seizures","volume":"12","author":"Ioannou","year":"2022","journal-title":"Brain Behav."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib48","first-page":"2025","article-title":"Phenytoin Toxicity. [Updated 2023 Aug 8]. StatPearls Publishing, Treasure Island (FL) Last updated: August 08 2023. Last accessed","volume":"25","author":"Iorga","year":"2023","journal-title":"October"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib49","series-title":"National Report on Medicines Use in Italy","author":"Italian Medicines Agency","year":"2019"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib50","series-title":"National Report on Medicines Use in Italy","author":"Italian Medicines Agency","year":"2020"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib51","series-title":"National Report on Medicines Use in Italy","author":"Italian Medicines Agency","year":"2020"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib52","series-title":"National Report on Medicines Use in Italy","author":"Italian Medicines Agency","year":"2021"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib53","series-title":"National Report on Medicines Use in Italy","author":"Italian Medicines Agency","year":"2022"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib54","series-title":"National Report on Medicines Use in Italy","author":"Italian Medicines Agency","year":"2023"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib55","series-title":"National Report on Medicines Use in Italy","author":"Italian Medicines Agency","year":"2024"},{"issue":"4","key":"10.1016\/j.eplepsyres.2025.107689_bib56","first-page":"224","article-title":"Risks associated with long-term benzodiazepine use","volume":"88","author":"Johnson","year":"2013","journal-title":"American family physician"},{"issue":"13","key":"10.1016\/j.eplepsyres.2025.107689_bib57","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1001\/jama.2022.3880","article-title":"Antiseizure medications for adults with epilepsy: a review","volume":"327","author":"Kanner","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.eplepsyres.2025.107689_bib58","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S1474-4422(15)00225-2","article-title":"Comorbidities of epilepsy: current concepts and future perspectives","volume":"15","author":"Keezer","year":"2016","journal-title":"Lancet Neurol."},{"issue":"9","key":"10.1016\/j.eplepsyres.2025.107689_bib59","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s40263-022-00940-2","article-title":"Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability","volume":"36","author":"Kienitz","year":"2022","journal-title":"CNS drugs"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib60","unstructured":"Latvian State Agency of Medicines. (2016). Baltic Statistics on Medicines 2013-2015. 2nd edition. Riga, Latvia. ISBN 978-9934-8602-2-5. Last updated: 2016. Last accessed: April 25 2025. https:\/\/www.zva.gov.lv\/sites\/default\/files\/2018-05\/Baltic%20Statistics%20on%20Medicines%202013%20-%202015.pdf."},{"issue":"1","key":"10.1016\/j.eplepsyres.2025.107689_bib61","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/jcpt.12615","article-title":"Factors limiting adherence to antiepileptic treatment: a French online patient survey","volume":"43","author":"Laville","year":"2018","journal-title":"J. Clin. Pharm. Ther."},{"issue":"2","key":"10.1016\/j.eplepsyres.2025.107689_bib62","doi-asserted-by":"crossref","first-page":"39","DOI":"10.14581\/jer.14010","article-title":"Old versus new: why do we need new antiepileptic drugs?","volume":"4","author":"Lee","year":"2014","journal-title":"J. Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib63","unstructured":"LICE). (2023). Guida alle epilessie, edizione 2023. Lsat updated: 2023. Last accessed: July 20 2025. \u3008https:\/\/www.lice.it\/pdf\/web_2023_guida_alle_epilessie.pdf\u3009."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib64","unstructured":"L\u00f3pez Gonz\u00e1lez, F.J., Haba, V.V., Centalles, M.F., Argany, M.T., Blanco, D.C., Fern\u00e1ndez, J.S. (2023). Recomendaciones diagn\u00f3stico-terap\u00e9uticas de la SEN2019. Manual de Pr\u00e1ctica Cl\u00ednica en Epilepsia. Sociedad Espa\u00f1ola de Neurolog\u00eda. ISBN: 978-84-17372-96-5. Last updated: June 2023. Last accessed: July 20 2025. \u3008https:\/\/www.sen.es\/pdf\/guias\/GuiaEpilepsia_2023.pdf\u3009."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2024.110170","article-title":"Impact of interaction among antiseizure medication polytherapy, clinical, sociodemographic and psychological factors on quality of life in patients with epilepsy: a systematic review","volume":"162","author":"Lozano-Garc\u00eda","year":"2025","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib66","volume":"1","author":"Ludwig","year":"2024"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108988","article-title":"Supply problems of antiseizure medication are common among epilepsy patients in Germany","volume":"138","author":"Mann","year":"2023","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib68","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.seizure.2022.06.004","article-title":"Persistent knowledge gaps between 2005 and 2020 in women with epilepsy: comparison of multicenter studies from Germany","volume":"100","author":"Mann","year":"2022","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib69","unstructured":"Ministerio de Sanidad. (2025). Consumo de Productos Farmac\u00e9uticos. Datos de consumo de recetas m\u00e9dicas del SNS seg\u00fan clasificaci\u00f3n Anat\u00f3mica-Terap\u00e9utica-Qu\u00edmica (ATC). Last updated: 2025. Last accessed: April 25 2025. \u3008https:\/\/www.sanidad.gob.es\/areas\/farmacia\/consumoMedicamentos\/ATC\/home.htm\u3009."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib70","unstructured":"Nakken, K.O., Brodtkorb, E. (2020). Are the new anti-eplieptic drugs any batter than teir predecessors? Perspectives. Tidsskr Nor Legeforen 2020 Vol. 140. doi: 10.4045\/tidsskr.20.0657."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib71","series-title":"Statistical Forecasting: Notes on Regression and Time Series Analysis","author":"Nau","year":"2020"},{"issue":"6","key":"10.1016\/j.eplepsyres.2025.107689_bib72","first-page":"CD001031","article-title":"Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review","volume":"6","author":"Nevitt","year":"2018","journal-title":"The Cochrane database of systematic reviews"},{"issue":"4","key":"10.1016\/j.eplepsyres.2025.107689_bib73","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11940-016-0401-x","article-title":"The role of benzodiazepines in the treatment of epilepsy","volume":"18","author":"Ochoa","year":"2016","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib74","unstructured":"Ochoa, J.G., Riche, W. (2024). Antiepileptic Drugs. Medscape. Last updated: June 7 2024. Last accessed: July 20 2025. \u3008https:\/\/emedicine.medscape.com\/article\/1187334-overview\u3009."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib75","unstructured":"OECD). (2024). OECD Health Statistics 2024. Definitions, Sources and Methods. Total pharmaceutical consumption by DDDs. Last updated: November 2024. Last accessed: April 04 2025. \u3008https:\/\/stats.oecd.org\/wbos\/fileview2.aspx?IDFile=6f2bfdca-6a41-4b50-9b47-b0a1a7d12a1e\u3009."},{"issue":"5","key":"10.1016\/j.eplepsyres.2025.107689_bib76","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1468-1331.2006.01268.x","article-title":"Use of antiepileptic drugs in Estonia: an epidemiologic study of adult epilepsy","volume":"13","author":"Oun","year":"2006","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.eplepsyres.2025.107689_bib77","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/epi.17877","article-title":"Which terms should be used to describe medications used in the treatment of seizure disorders? An ILAE position paper","volume":"65","author":"Perucca","year":"2024","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib78","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.seizure.2019.07.001","article-title":"Valproate utilisation trends among girls and women from 2013 to 2018","volume":"70","author":"Puteikis","year":"2019","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.eplepsyres.2025.107689_bib79","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00228-016-2168-0","article-title":"Antiepileptic drug use in Italian children over a decade","volume":"73","author":"Putignano","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.eplepsyres.2025.107689_bib80","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.jsps.2020.08.013","article-title":"Need for pharmacoeconomic consideration of antiepileptic drugs monotherapy treatment in persons with epilepsy","volume":"28","author":"Sarangi","year":"2020","journal-title":"Saudi Pharm. J."},{"issue":"12","key":"10.1016\/j.eplepsyres.2025.107689_bib81","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/j.1468-1331.2007.01970.x","article-title":"Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000-2005","volume":"14","author":"Savica","year":"2007","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107210","article-title":"Usage of antiepileptic drugs in different diseases in Germany - a retrospective study","volume":"111","author":"Scholten","year":"2020","journal-title":"Epilepsy Behav."},{"issue":"9","key":"10.1016\/j.eplepsyres.2025.107689_bib83","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.tips.2018.06.006","article-title":"Rethinking pharmacological nomenclature","volume":"39","author":"Seifert","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib84","series-title":"Basic Knowledge of Pharmacology","author":"Seifert","year":"2018"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib85","article-title":"Global, regional, and national time trends in the burden of epilepsy, 1990\u20132019: an age-period-cohort analysis for the global burden of disease 2019 study","volume":"15","author":"Shan","year":"2024","journal-title":"Front. Neurol. Sec. Epilepsy"},{"issue":"2","key":"10.1016\/j.eplepsyres.2025.107689_bib86","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/157015909788848866","article-title":"Antiepileptic drug monotherapy: the initial approach in epilepsy management","volume":"7","author":"St Louis","year":"2009","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib87","unstructured":"State Agency of Medicines. (2013). Statistics on Medicines Consumption 2012. Last updated: 2013. Last accessed: April 25 2025. \u3008https:\/\/www.zva.gov.lv\/sites\/default\/files\/2018-05\/Zalu_paterina_statistika_2012-20130604.pdf\u3009."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib88","unstructured":"State Medicines Control Agency of Lithuania. (2019). Baltic Statistics on Medicines 2016-2018. Vilnius, Lithuania. ISBN 978-609-462-139-0. Last updated: 2019. Last accessed: April 25 2025. https:\/\/www.zva.gov.lv\/sites\/default\/files\/2020-01\/Baltic%20statistics_3rd%20edition.pdf."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib89","unstructured":"State Medicines Control Agency of Lithuania. (2023a). Medicines consumption (2022). Last updated: September 10 2023. Last accessed: April 25 2025. \u3008https:\/\/vvkt.lrv.lt\/media\/viesa\/saugykla\/2023\/9\/5gjLnBtWc7s.docx\u3009."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib90","unstructured":"State Medicines Control Agency of Lithuania. (2023b). Suaugusi\u0173j\u0173 Epilepsijos Prevencijos, Diagnostikos, Gydymo, Medicinin\u0117s Reabilitacijos IR Slaugos Metodika. Last updated: August 2023. Last accessed: July 20 2025. \u3008https:\/\/sam.lrv.lt\/public\/canonical\/1728889291\/26136\/Epilepsija_galutinis.pdf\u3009."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2024.110162","article-title":"Shortage of antiseizure medication in Germany: how big is the problem?","volume":"162","author":"Steidl","year":"2025","journal-title":"Epilepsy Behav."},{"issue":"2-3","key":"10.1016\/j.eplepsyres.2025.107689_bib92","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.eplepsyres.2011.09.008","article-title":"Antiepileptic drug combinations--have newer agents altered clinical outcomes?","volume":"98","author":"Stephen","year":"2012","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib93","series-title":"StatPearls [Internet]","article-title":"Seizure medications","author":"Subbarao","year":"2023"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib94","unstructured":"Sundhedsdatastyrelsen. (2024). Medstat.dk. The Danish Health Data Authority, Copenhagen. Last updated: March 2024. Last accessed: May 10 2025. \u3008https:\/\/www.medstat.dk\/en\u3009."},{"issue":"4","key":"10.1016\/j.eplepsyres.2025.107689_bib95","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3390\/ijerph18041382","article-title":"Financing healthcare in central and eastern european countries: how far are we from universal health coverage?","volume":"18","author":"Tambor","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"3","key":"10.1016\/j.eplepsyres.2025.107689_bib96","doi-asserted-by":"crossref","first-page":"135","DOI":"10.5698\/1535-7511-13.3.135","article-title":"The current state of absence epilepsy: can we have your attention?","volume":"13","author":"Tenney","year":"2013","journal-title":"Epilepsy currents"},{"issue":"12","key":"10.1016\/j.eplepsyres.2025.107689_bib97","doi-asserted-by":"crossref","first-page":"5945","DOI":"10.1007\/s00415-023-11958-x","article-title":"Clinical and economic implications of epilepsy management across treatment lines in Spain: a real-life database analysis","volume":"270","author":"Toledano","year":"2023","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.eplepsyres.2025.107689_bib98","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3390\/ijerph21020206","article-title":"Pharmaceutical and recreational drug usage patterns during and post COVID-19 determined by Wastewater-Based epidemiology","volume":"21","author":"Tomsone","year":"2024","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"6","key":"10.1016\/j.eplepsyres.2025.107689_bib99","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1600-0404.2006.00639.x","article-title":"Trends in utilization of antiepileptic drugs in Denmark","volume":"113","author":"Tsiropoulos","year":"2006","journal-title":"Acta Neurol. Scand."},{"issue":"2","key":"10.1016\/j.eplepsyres.2025.107689_bib100","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/14737175.2020.1707668","article-title":"The role of polytherapy in the management of epilepsy: suggestions for rational antiepileptic drug selection","volume":"20","author":"Verrotti","year":"2019","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib101","series-title":"Critical Care Toxicology","article-title":"Barbiturates","author":"Walsh","year":"2016"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib102","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.seizure.2018.11.018","article-title":"Substitution has better efficacy than add-on therapy for patients with focal epilepsy after their first antiepileptic drug treatments fail","volume":"64","author":"Wang","year":"2019","journal-title":"Seizure. Eur. J. Epilepsy"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib103","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.eplepsyres.2018.07.011","article-title":"Antiepileptic drug prescription in Dutch children from 2006-2014 using pharmacy-dispensing data","volume":"146","author":"Weijenberg","year":"2018","journal-title":"Epilepsy Res."},{"issue":"8","key":"10.1016\/j.eplepsyres.2025.107689_bib104","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1007\/s00103-018-2768-1","volume":"61","author":"Wentzell","year":"2018","journal-title":"Bundesgesundheitsblatt Gesundh. Gesundh."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib105","unstructured":"Wertheimer, A.I., Santella, T.M. (2007). Problems using the Defined Daily Dose (DDD) as a statistical basis for drug pricing and reimbursement. International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and F\u00e9d\u00e9ration Internationale de l\u2019Industrie du M\u00e9dicament (FIIM). Last updated: 2007. Last accessed: October 05 2025. \u3008https:\/\/www.ifpma.org\/wp-content\/uploads\/2023\/01\/i2023_IFPMA_DDD_2007_EN.pdf\u3009."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib106","unstructured":"WHO). (2024). ATC\/DDD Index. N03A antiepileptics. Last updated: December 27 2024. Last accessed: July 10 2025. \u3008https:\/\/atcddd.fhi.no\/atc_ddd_index\/?code=n03a\u3009."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib107","unstructured":"Wissenschaftliches Institut der AOK (WIdO). (2024). PharMaAnalyst. Last updated: October 07 2024. Last accessed: April 25 2025. \u3008https:\/\/arzneimittel.wido.de\/PharMaAnalyst\u3009."},{"issue":"5","key":"10.1016\/j.eplepsyres.2025.107689_bib108","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40258-019-00487-2","article-title":"General trends in prices and prescription patterns of antiseizures in Germany between 2000 and 2017: analysis of national and Cohort-Based data","volume":"17","author":"Willems","year":"2019","journal-title":"Appl. Health Econ. Health Policy"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib109","unstructured":"World Health Organization (WHO) (2023). Antiseizure medicines for management of epilepsy in adults and children. Last updated: 2023. Last accessed: July 10 2025. \u3008https:\/\/www.who.int\/teams\/mental-health-and-substance-use\/treatment-care\/mental-health-gap-action-programme\/evidence-centre\/epilepsy-and-seizures\/antiseizure-medicines-for-management-of-epilepsy-in-adults-and-children\u3009."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib110","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s41043-025-00783-9","article-title":"Global trends and burden of idiopathic epilepsy: regional and gender differences from 1990 to 2021 and future outlook","volume":"44","author":"Xu","year":"2025","journal-title":"J. Health Popul Nutr."},{"key":"10.1016\/j.eplepsyres.2025.107689_bib111","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.seizure.2023.07.025","article-title":"Felt stigma proportion in people living with epilepsy: a systematic review","volume":"111","author":"Yang","year":"2023","journal-title":"Seizure Eur. J. Epilepsy"},{"issue":"1","key":"10.1016\/j.eplepsyres.2025.107689_bib112","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/epi4.12306","article-title":"The provision of epilepsy care across Europe 2017: a 17-year follow-up survey","volume":"4","author":"Zelano","year":"2019","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.eplepsyres.2025.107689_bib113","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.seizure.2023.10.016","article-title":"Prevalence and nature of patient-reported antiseizure medication side effects in a Swedish regional multi-center study","volume":"113","author":"Zelano","year":"2023","journal-title":"Seizure. Eur. J. Epilepsy"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121125001901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121125001901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T20:42:41Z","timestamp":1764016961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121125001901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":113,"alternative-id":["S0920121125001901"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2025.107689","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends, prescribing patterns and projections of antiseizure drug use in Europe","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2025.107689","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107689"}}